Törnkvist H, Bauer F C, Lindholm T S, Nilsson O S
Scand J Rheumatol. 1985;14(2):197-200. doi: 10.3109/03009748509165504.
Decalcified bone matrix pieces were prepared from growing rats treated for 3 weeks with subcutaneous injections of indomethacin 2 mg/kg/day or saline, and implanted into growing rats. Of the 16 recipients with 'saline implants', 8 received saline and another 8 indomethacin 2 mg/kg/day in subcutaneous injections. In another 16 recipients with 'indomethacin implants', 8 received saline and 8 indomethacin. As in previous studies, it was found that indomethacin exerted a mild inhibition of new bone formation expressed as decreased amount of ash weight in implants. The amount of ash weight and 45Ca specific activity of implants in recipients with implants from indomethacin-treated donor animals was not altered. These findings indicate that indomethacin is unable to modify the osteo-inductive properties of bone matrix.
将生长中的大鼠皮下注射吲哚美辛2毫克/千克/天或生理盐水,持续3周,然后制备脱钙骨基质片,并植入生长中的大鼠体内。在16只接受“生理盐水植入物”的受体中,8只接受皮下注射生理盐水,另外8只接受皮下注射吲哚美辛2毫克/千克/天。在另外16只接受“吲哚美辛植入物”的受体中,8只接受生理盐水,8只接受吲哚美辛。与之前的研究一样,发现吲哚美辛对新骨形成有轻微抑制作用,表现为植入物中灰分重量减少。来自吲哚美辛处理供体动物的植入物受体中,植入物的灰分重量和45Ca比活性没有改变。这些发现表明,吲哚美辛无法改变骨基质的骨诱导特性。